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Multiple pathways of recombination define cellular responses
to cisplatin
Zoran Z Zdraveski1, Jill A Mello1, Martin G Marinus2 and John M Essigmann1
Background: Cisplatin is a DNA-damaging drug used for treatment of testicular
tumors. The toxicity of cisplatin probably results from its ability to form DNA
adducts that inhibit polymerases. Blocked replication represents a particular
challenge for tumor cells, which are committed to unremitting division.
Recombination provides a mechanism by which replication can proceed
despite the presence of lesions and therefore could be significant for managing
cisplatin toxicity. 
Results: Recombination-deficient Escherichia coli mutants were strikingly
sensitive to cisplatin when compared with the parental strain. Our data identified
both daughter-strand gap and double-strand break recombination pathways as
critical for survival following treatment with cisplatin. Although it is established
that nucleotide excision repair (NER) significantly protects against cisplatin
toxicity, most recombination-deficient strains were as sensitive to the drug as the
NER-deficient uvrA mutant. Recombination/NER deficient double mutants were
more sensitive to cisplatin than the corresponding single mutants, suggesting
that recombination and NER pathways play independent roles in countering
cisplatin toxicity. Cisplatin was a potent recombinogen in comparison with the
trans isomer and canonical alkylating agents. Mitomycin C, which like cisplatin,
forms DNA cross-links, was also recombinogenic at minimally toxic doses.
Conclusions: We have demonstrated that all of the major recombination
pathways are critical for E. coli survival following treatment with cisplatin.
Moreover, recombination pathways act independently of NER and are of equal
importance to NER as genoprotective systems against cisplatin toxicity. Taken
together, these results shed new light on how cells survive and succumb to this
widely used anticancer drug. 
Introduction
The cytotoxicity of many DNA-damaging agents is
believed to result from the formation of lesions that block
the processivity of DNA polymerases and cause replication
arrest [1]. Replication arrest, in turn, leads to the formation
of secondary DNA damage such as daughter-strand gaps
and double-strand breaks [2]. If uncorrected, such damage
can be lethal because of both the loss of essential genes
and faulty chromosomal segregation; all organisms, there-
fore, have developed strategies for repair of these types of
damage. In Escherichia coli, the principal mechanism for
repair of daughter-strand gaps and double-strand breaks is
recombination, in which the injured DNA strand is paired
with an intact homologous strand that provides a template
for repair of the secondary lesion (for reviews see [1–3]). 
The widely used chemotherapeutic drug cisplatin (cis-
diamminedichloroplatinum(II); Figure 1a) is toxic to
cells and is strikingly effective against testicular tumors
[4]. Although the cytotoxicity of cisplatin is attributed to
its capacity to damage DNA, the detailed molecular
mechanism to account for the therapeutic efficacy and
organotropic specificity of this drug remains elusive. Cis-
platin binds to the N7 atom of purine bases in DNA to
form predominantly 1,2-d(GpG) (Figure 1b), 1,2-d(ApG)
and 1,3-d(GpNpG) (in which N is any nucleotide)
intrastrand cross-links, and a small percentage of inter-
strand crosslinks (between two guanines in complemen-
tary strands; Figure 1b) [5,6]. These DNA adducts elicit
a variety of cellular responses, including inhibition of
DNA synthesis. The 1,2-intrastrand cross-links, in partic-
ular, are strong blocks to replication in vitro and in vivo
[7,8]. Cisplatin induces recombination in Candida albi-
cans [9] and Drosophila melanogaster [10], and it induces
meiotic crossing-over in germ cells of mice [11]. Recom-
bination deficient mutants, such as recA and recBC in
E. coli [12–14], RAD52 in Saccharomyces cerevisae [15,16],
and RAD21 and RAD22 in Schizosaccharomyces pombe [17],
show sensitivity to cisplatin. Remarkably, despite these
observations, there has been no systematic analysis to
date of recombination as a strategy for managing DNA
damage caused by cisplatin. To address this gap in
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understanding, we assembled a series of E. coli strains
that were deficient in the major pathways of recombina-
tion and studied their responses to treatment with the
drug. We report that recombination-deficient mutants
showed exceptionally high sensitivity to cisplatin in com-
parison to their parental strain. Indeed, most recombina-
tion-deficient mutants were as sensitive to cisplatin as
were mutants lacking nucleotide excision repair (NER).
Recombination/NER- deficient double mutants pro-
duced increased sensitivity to cisplatin indicating that
these two pathways act independently in the cellular
defenses against the drug. In addition, we found that
even modestly toxic doses of cisplatin were potently
recombinogenic when compared with other DNA-dam-
aging agents. The results suggest a model for cisplatin
cytotoxicity that can accommodate the currently known
cellular effects of the drug and might account for the
therapeutic specificity of cisplatin.
Results
Mutants deficient in the initiation of recombination are
hypersensitive to cisplatin
Two pathways can initiate recombinational repair in
E. coli: the RecFOR pathway for the repair of daughter
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Figure 1
Structures of DNA-damaging agents used in
this study. (a) Structures of
diamminedichloroplatinum(II) isomers.
(b) Structures of cisplatin–DNA cross-links.
(c) Chemical structures of other DNA-
damaging agents used in this study.
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strand gaps and the RecBCD pathway for the repair of
double-strand breaks. Daughter strand gaps are formed
when the processivity of the replication fork is interrupted
by a noncoding DNA lesion, such as a UV-induced dimer,
in the template strand, and the lesion is left opposite a
single-stranded (ss) gap in the nascent strand [18]. Genetic
evidence implicates proteins of the RecFOR pathway in
the recombinational repair of UV-induced daughter strand
gaps [19]. Biochemical studies demonstrate that the
RecOR complex promotes the binding of RecA protein to
ss DNA (in the presence of ss DNA binding protein), and
it facilitates the homologous pairing by RecA [20]. The
RecFR complex is thought to interact directly with the
stalled replication fork, and it might function in fork disas-
sembly or reassembly during recombination and repair
[21,22]. To assess the importance of the RecFOR pathway
in the cellular response to cisplatin DNA damage, we
examined the survival of recF, recO and recR mutants after
treatment with cisplatin (Figure 2a). At the highest cis-
platin dose (100 µM), the surviving fraction for each
mutant was approximately three orders of magnitude
lower than that for the isogenic wild-type strain. The high
sensitivity of these mutants is consistent with a role of the
RecFOR gene products in recombinational repair of
daughter strand gaps produced as a consequence of repli-
cation blockage by cisplatin adducts.
In E. coli the RecBCD pathway is essential for recombi-
national repair of X-ray-induced double-strand breaks
[23]. The RecBCD complex combines helicase and
nuclease functions that simultaneously unwind and asym-
metrically degrade double-strand breaks (the strand with
the 3′ terminus is nicked more frequently than the strand
with the 5′ end). Once the enzyme complex encounters a
χ sequence (5′-GCTGGTGG-3′) from the 3′ direction, it
pauses and nicks the DNA to generate a 3′ ss DNA tail
that serves as a substrate for RecA polymerization and ini-
tiation of recombination [24,25] (reviewed in [26,27]). To
determine if the RecBCD pathway participates in the cel-
lular processing of cisplatin-induced DNA damage, we
examined the two major phenotypes shown by recBCD
mutants. The recBC mutant is deficient in normal helicase
and nuclease activities and it is sensitive to DNA-damag-
ing treatments [28]. In agreement with previous reports
[12], the recBC mutant showed high sensitivity to cis-
platin (Figure 2b). The surviving fraction for the recBC
strain at a cisplatin dose of 75 µM was approximately four
orders of magnitude lower than for the parental wild-type
strain. The recD mutant is defective for normal nuclease
activity, and it exhibits wild-type sensitivity to DNA-
damaging agents [29]. In contrast to the results with the
recBC strain, the recD mutant showed little or no sensitiv-
ity to cisplatin. These data provided genetic evidence
that cisplatin-damaged DNA resulted in the formation of
double-strand breaks. 
Mutants deficient in resolution of recombination
intermediates are also hypersensitive to cisplatin
Both the RecFOR and RecBCD pathways mediate the
formation of RecA nucleoprotein filaments on ss DNA.
These filaments catalyze the pairing and the strand
exchange reactions between the damaged DNA molecule
and an intact homologous duplex. The cisplatin hyper-
sensitivity of recA mutants is well documented [13,14] and
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Figure 2
Survival of E. coli strains treated with cisplatin.
For each data point, results shown are the
mean of at least three independent
experiments plated in duplicate, ± SEM.
(a) Effects of recF, recO and recR mutations
on cisplatin sensitivity. (b) Effects of recBC
and recD mutations on cisplatin sensitivity. 
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was confirmed in this investigation (data not shown). The
ensuing cross-over converts the damage-containing strand
into duplex DNA and results in the formation of a four-
way Holliday junction. In the late steps of recombination,
the Holliday junction is subjected to the branch migration
activities of either the RuvAB complex or the RecG
protein [30,31], and it is cleaved by the RuvC resolvase
[32]. Accordingly, we tested individual ruvA, ruvC and recG
mutants, as well as a ruvC recG double mutant, for sensitiv-
ity to cisplatin. It should be noted that the transposon
insertion in the ruvA60 mutant has a polar effect on ruvB
expression [33]. As shown in Figure 3, the individual ruvA
and ruvC mutants showed a striking sensitivity to cisplatin
that was equal or greater in magnitude to that observed for
the mutants deficient in the RecBCD and RecFOR path-
ways of recombination. At a cisplatin concentration of
80 µM, the ruvA and ruvC strains exhibited a decreased
survival of approximately four orders of magnitude in com-
parison with the wild-type strain. The sensitivities of these
mutants indicated that branch migration and resolution of
Holliday junctions by the RuvABC pathway were of criti-
cal importance, along with the earlier stages of recombina-
tion, for the post-replicative repair of cisplatin DNA
damage. In contrast to the RuvABC-deficient strains, the
recG mutant was found to be only tenfold more sensitive to
cisplatin than the parental strain at a cisplatin dose of
80 µM. The ruvC recG double mutant, deficient for both
pathways of branch migration and resolution, showed an
additive effect, exhibiting higher sensitivity than either
individual mutant strain. This observation is consistent
with previous suggestions that the RecG and RuvABC
pathways do not overlap significantly [34]. Taken
together, these results indicate that RuvABC function is as
important as RecBCD function for cell survival following
cisplatin DNA damage, and that the RecG pathway plays a
comparatively minor role that is independent of RuvABC
in the processing of cisplatin damage.
Recombination deficient and nucleotide excision repair
(NER) deficient strains are equally sensitive to cisplatin
In order to appraise the significance of the results of the
previous experiments, we compared the cisplatin sensitiv-
ity of recombination deficient mutants with a strain defi-
cient in NER. NER acts on a broad range of DNA
damages and has been assigned the central role in modu-
lating the sensitivity of eukaryotic and prokaryotic cells to
cisplatin. Cisplatin intrastrand adducts are removed from
DNA by the NER repair system in vivo and by a reconsti-
tuted NER system in vitro [35]. Mutations that impair the
function of this system cause hypersensitivity to cisplatin
that is held as a benchmark for mutant susceptibility to
the drug. Accordingly, we compared survival following cis-
platin treatment of the NER deficient strain uvrA with
that for representative recombination deficient strains:
recF, recBCD and ruvABC (Figure 4). The NER-deficient
strain showed hypersensitivity to cisplatin as previously
described [12,36] but, interestingly, not higher than
mutants deficient in the RecBCD or RuvABC functions.
The survival curves for uvrA, recBCD and ruvABC strains
essentially overlapped, whereas only the recF mutant was
slightly less sensitive than uvrA. The comparable sensitiv-
ities of these mutants establish a crucial role for recombi-
nation alongside NER in determining cell survival
following cisplatin DNA damage. 
Recombination/nucleotide excision repair (NER) deficient
double mutants show increased sensitivity to cisplatin
The comparable sensitivity of the recombination and
NER-deficient single mutants presented in Figure 4
posed the question of whether or not the two pathways
(recombination and NER) act independently in the pro-
cessing of cisplatin-induced DNA damage. We addressed
this question by comparing the effects of cisplatin on the
survival of recombination and NER single and double
mutants. If a double mutant showed an increased sensitiv-
ity to cisplatin in comparison to the parental single
mutants, this would suggest that recombination and NER
are non-overlapping pathways for the repair of cisplatin
damage. We constructed a series of recombination/NER
deficient double mutants: recF uvrA, recBCD uvrA, ruvA
uvrA and ruvC uvrA, and tested them for sensitivity to cis-
platin. As shown in Figure 4, all of the tested double
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Figure 3
Effects of recG, ruvA, ruvC and ruvC recG mutations on cisplatin
sensitivity in E. coli. For each data point, results shown are the mean of
at least three independent experiments plated in duplicate, ± SEM. 
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mutants showed decreased survival. The recF uvrA and
the recBCD uvrA double mutants showed comparable sen-
sitivities, and both showed higher sensitivity than the cor-
responding single mutants (Figure 4a). In the same
manner, ruvA uvrA and ruvC uvrA double mutants also
showed increased sensitivities in comparison with the
analogous single mutants (Figure 4b). At the relatively low
cisplatin dose of 10 µM, all of the recombination/NER
double mutants tested showed a striking reduction in sur-
vival of approximately four orders of magnitude in com-
parison to the parental wild-type strain. Taken together,
these results suggest that the recombination and the NER
pathways act independently of each other in protecting
the cell from cisplatin-induced damage. 
Recombination deficient mutants show low sensitivity to
trans-DDP
The trans isomer of cisplatin, trans-diamminedichloro-
platinum(II) (trans-DDP; Figure 1a), also reacts with DNA
to generate a spectrum of N7 intrastrand and interstrand
cross-links [37,38], but it is far less cytotoxic than cisplatin
and it is ineffective against tumors. Consequently, trans-
DDP is a useful reference compound for calibrating the rel-
ative significance of various cellular responses to cisplatin.
To determine whether the extreme sensitivities of recom-
bination mutants were unique to the therapeutically active
cis isomer, we tested the same panel of isogenic mutants
(recF, recBCD, ruvABC and uvrA) for survival after trans-
DDP treatment (Figure 5). The uvrA strain showed slightly
higher sensitivity to trans-DDP in comparison with the wild
type, as previously reported [13]. The recombination-defi-
cient mutants recF, recBCD and ruvABC showed similarly
modest sensitivity (again, in comparison to the wild type),
even at trans-DDP concentrations of 150 µM. The lack of
sensitivity of these mutants suggested that, in contrast to
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Figure 4
Comparison of cisplatin sensitivities in E. coli
recombination and NER single mutants and
recombination/NER double mutants. For each
data point, results shown are the mean of at
least three independent experiments plated in
duplicate, ± SEM. (a) Effects of uvrA, recF,
recBCD, recF uvrA and recBCD uvrA
mutations on cisplatin sensitivity (recF survival
profile from Figure 2a is shown for
comparison). (b) Effects of uvrA, ruvABC,
ruvA uvrA and ruvC uvrA mutations on
cisplatin sensitivity.
Figure 5
Survival of uvrA, ruvABC, recBCD and recF E. coli strains treated with
trans-DDP. For each data point, results shown are the mean of at least
three independent experiments plated in duplicate, ± SEM.
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cisplatin, trans-DDP did not result in significant levels of
either daughter strand gaps or double-strand breaks that
require homologous recombination for their repair. 
Cisplatin is highly recombinogenic
The extreme cisplatin sensitivity of recombination defi-
cient strains underscores the importance of recombination
strategies for cell survival following cisplatin exposure.
These observations suggested that cisplatin might induce
high levels of recombination events in surviving popula-
tions. We next, therefore, examined the relative amounts
of drug-induced recombination for a panel of compounds
including cisplatin, the alkylating agents N-methyl-N′-
nitro-N-nitrosoguanidine (MNNG), methylmethane sul-
fonate (MMS), streptozotocin (STZ) and the bifunctional
cross-linking agents mitomycin C (MMC) and trans-DDP
(for chemical structures of the compounds see Figure 1c).
An assay was used in which inverted inactive lac operons
could be made functional only through a recombination
event (Figure 6). Induced Lac+ recombinants appeared
within a lawn of Lac– cells as concentrated zones of red
colonies around a drug-containing disk, whereas sponta-
neous recombinants appeared as sparse red colonies over
the entire plate. The cytotoxicity of the drug was visible as
a clear cell-free zone surrounding the disk. As shown in
Figure 7, at approximately equal cytotoxic doses (deter-
mined by the approximate radius of the zone of killing) cis-
platin stimulated an extremely high number of Lac+
recombinants as compared with other DNA-damaging
agents. The alkylating agents MNNG, MMS and STZ
induced some recombinants, but they showed high levels
of cytotoxicity without stimulating correspondingly high
levels of recombination. The therapeutically inactive trans
isomer of cisplatin showed almost no induction of Lac+
recombinants, even at the highest dose tested (120 nmol;
3 o’clock in Figure 7). At this trans-DDP dose the level of
toxicity achieved was roughly equal to that of the lowest
dose of cisplatin (30 nmol; 9 o’clock in Figure 7). This
result correlated with our observation that recombination
deficient mutants showed little sensitivity to the trans
isomer. Only MMC, which forms covalent adducts with
the exocyclic amines of guanines and abundant interstrand
cross-links [39], showed comparable recombinogenicity to
cisplatin. This result poses the possibility that the inter-
strand cross-links of cisplatin and MMC might be the
lesions that induce recombinogenicity. It must be noted,
however, that the levels of interstrand cross-links in our
experiments were not measured and therefore we cannot
make a correlation between recombinogenicity and inter-
strand cross-links at this time. We also note that trans-DDP
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Figure 6
Assay for drug-induced recombination.
(a) Schematic of the chromosome of the lac
diploid strain GM7330 showing the normally
present lac locus (blue) and the inserted
duplicate but reverse, φ80dIIlac locus (green).
The black boxes represent the deletions that
render the strain lac–. (b) A recombination
event between the two incomplete lac loci
yields a functional lac+ product. (c) Schematic
of the experimental set up: drug was applied
to filter disks, in increasing amounts counter
clockwise, to a lawn of GM7330 on
MacConkey agar plates. The clear zone
surrounding the disks is the zone of killing by
the drug. The lac+ recombinants grow as
concentrated zones of red colonies around
the drug disks (or the zone of killing). The
sporadic red colonies over the entire plate are
spontaneous recombinants.
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forms interstrand cross-links in vitro [37], but this com-
pound did not induce a significant number of recombi-
nants in our assay. This result possibly reflects the fact that
the interstrand cross-links of trans-DDP might form less
frequently in vivo than they do in vitro (i.e., few interstrand
lesions might have been formed at the concentrations of
trans-DDP used) [40,41]. Regardless of which lesion
induces recombination, the high ratio of recombination to
cytotoxicity for cisplatin and MMC, when compared with
that found for the other DNA-damaging drugs and trans-
DDP, might provide an important key to understanding
the therapeutic activities of these two compounds.
Discussion
This study was an analysis of the role of recombination as
a cellular defense against cisplatin. The results showed
that E. coli recombination-deficient mutants recF, recO,
recR, recBC, recBCD, ruvA, ruvC, ruvABC, recG and ruvC
recG, were strikingly sensitive to the drug. The sensitivi-
ties of the recombination-deficient mutants were compa-
rable to the cisplatin sensitivity of the NER deficient
strain (uvrA). This result is significant because, until this
work, NER was considered the pathway of greatest impor-
tance as a cellular defense against cisplatin-induced
damage. Recombination/NER deficient double mutants
(recF uvrA, recBCD uvrA, ruvA uvrA and ruvC uvrA) pro-
duced increased sensitivity to cisplatin, underscoring the
possibility that recombination and excision repair path-
ways might be independent strategies for managing the
DNA damage induced by this drug. 
Our results indicated that recombination proteins are
required for survival following cisplatin-induced DNA
damage. On the basis of current models, there are two
major pathways for recombinational repair and homolo-
gous recombination in bacteria [1–3]. The daughter strand
gap repair pathway requires the RecFOR and the RecA,
RuvABC and/or RecG gene products (Figure 8a), and the
double-strand break repair pathway requires the RecBCD
and RecA, RuvABC and/or RecG gene products (Figure 8b).
Given that mutants deficient in the gene products
involved in both pathways showed high sensitivity to cis-
platin we can make the conclusion that cisplatin-induced
DNA damage led to the formation of both daughter strand
gaps and double-strand breaks. Although the formation of
daughter strand gaps (Figure 8a) as a result of replication
blocks is consistent with the knowledge that cisplatin
inhibits DNA synthesis, the induction of double-strand
breaks is not widely associated with the activities of the
drug. Cisplatin does not react with DNA in a manner that
would lead directly to strand breaks or abasic sites, and
therefore double-strand breaks must arise following expo-
sure to cisplatin as indirect, secondary DNA lesions. Cis-
platin DNA damage could lead to the formation of
double-strand breaks following the encounter of a replica-
tion fork with an unrepaired daughter strand gap caused
by a cisplatin adduct in the previous round of replication
(Figure 8b). An unrepaired daughter strand gap could also
lead to the formation of double-strand breaks because of
the activities of single strand endonucleases [1]. Alterna-
tively, double-strand breaks could be formed by cisplatin
adducts via a recently proposed model in which induced
replication arrest results in a double-strand break through
the annealing of the ends of the complementary, newly
synthesized daughter strands [42].
It has been discovered that cisplatin–DNA cross-links are
uniquely recognized by a variety of cellular proteins (adduct
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Figure 7
Lac+ recombinants induced by DNA-damaging agents in the E. coli
strain GM7330. Doses applied to filter disks increase counter
clockwise from 12 o’clock position for all compounds: cisplatin: 0, 30
60, 120 nmoles; N-methyl-N′-nitro-N-nitrosoguanidine (MNNG): 0, 5,
10, 20 µg; streptozotocin (STZ): 0, 10, 20, 40 µg; trans-DDP: 0, 30,
60, 120 nmoles; methylmethane sulfonate (MMS): 0, 0.65, 1.3, 2.6 µg;
and mitomycin C (MMC): 0, 0.05, 0.1, 0.2 µg.
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binding proteins, or ABPs in Figure 8), and many of these
interactions have been proposed to play a key role in the
mechanism of action of the drug [35,43]. In the context of
our present findings, protein recognition of cisplatin cross-
links might contribute to the formation of daughter strand
gaps and double-strand breaks. For example, an ABP could
contribute to a replication arrest by providing an exception-
ally strong block to the processivity of DNA polymerases, as
has been shown for the rat high mobility group protein
HMG-1 [44] (Figure 8, step 1). Alternatively, specialized
ABPs could introduce strand breaks via enzymatic nicking
activities at sites of cisplatin cross-links. For example, T4
endonuclease VII nicks DNA site-specifically at a cisplatin
1,2-d(GpG) cross-link [45], and it is possible that other pro-
teins possess similar activities. It has also been proposed
that mismatch repair proteins, which selectively recognize
cisplatin–DNA adducts [46–48], could initiate repair events
targeted to the newly synthesized strand opposite a cis-
platin cross-link, leaving the offending lesion intact and
leading to an iterative process of excision and resynthesis.
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Figure 8
Models for recombinational repair of
secondary DNA lesions (defined here as
daughter-strand gaps and double-strand
breaks) induced by cisplatin damage. Models
are based upon [64,65]. (a) daughter-strand
gap pathway. Step 1: The replication complex
encounters persistent cisplatin–DNA adducts
(perhaps because of poor NER of the 1,2
intrastrand cross-link). Stalled replication
results in the formation of a daughter-strand
gap opposite the adduct. The presence of an
adduct binding protein (ABP) might present
an even stronger block to replication than the
adduct alone. Step 2: Interactions between
the proteins of the RecFOR pathway and the
replication fork initiate RecA nucleation and
strand exchange. Step 3: The ensuing RecA
catalyzed strand exchange (with the aid of the
RecFOR accessory proteins) results in the
formation of a Holliday junction. Step 4:
Branch migration of the Holliday junction
catalyzed by the RecA, RuvAB or RecG
proteins results in the repair of the daughter-
strand gap and restoration of the replication
fork. Step 5: Resolution of the Holliday
junction by RuvC restores two double-
stranded DNA molecules. This could be a
mechanism of damage tolerance as the
cisplatin adduct is bypassed by
recombinational repair and persists in the
DNA. (b) double-strand break pathway. Step
6: The replication complex encounters an
unrepaired daughter-strand gap or a nick
opposite the adduct. Collapse of the
replication fork forms a double-strand break
and a daughter-strand gap; the daughter-
strand gap portion of the collapsed
replication fork is processed by the daughter-
strand gap pathway (a). There are other
mechanisms by which the double-strand
breaks could arise, and we have presented
only one scenario. By the proposed scheme,
repair of the double-strand breaks requires an
intact homolog of the damaged duplex. Step
7: The RecBCD complex (shown in red)
binds the free end of the double-strand break
and generates ss DNA that is a substrate for
RecA nucleation. Step 8: RecA nucleoprotein
filaments catalyze the invasion of the
RecBCD generated ss tail into the
homologous duplex. Step 9: RecA catalyzed
strand exchange and branch migration results
in the formation of a Holliday junction and
restoration of the replication fork. Step 10:
Resolution of the Holliday junction by RuvC
yields two intact duplexes (only one molecule
is shown).
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In these cases, such errant nucleolytic activities would
result in direct or post-replicative formation of double-
strand breaks that would require recombination for their
repair. We do not know if there are ABPs that recognize
MMC adducts but, given the similarities in recombino-
genicity of cisplatin and MMC, it would be interesting to
examine cellular extracts for such proteins.
Cisplatin forms a variety of DNA adducts and the specific
lesion responsible for cisplatin cytotoxicity remains unde-
fined. In the context of this study, it is reasonable to specu-
late that the highly abundant 1,2-intrastrand cross-links
(~90% of all adducts formed in vitro) led to frequent replica-
tion arrests and contributed significantly to formation of
daughter strand gaps and double-strand breaks. This inter-
pretation is based on several lines of reasoning (reviewed in
[8,35]): first, the 1,2-intrastrand cisplatin–DNA cross-links
are inefficiently repaired by NER compared with the minor
1,3-d(GpNpG) cross-link (6–8% of all adducts) and are
therefore persistent; second, the 1,2-intrastrand cross-links
inhibit phage and E. coli polymerases in vitro and in vivo
more strongly than the 1,3-intrastrand cross-links; and third,
the recombination mutants in our study exhibited low sensi-
tivity to trans-DDP, which does not form 1,2-intrastrand
cross-links because of geometric constraints. It is notewor-
thy that a single 1,2-d(GpG) intrastrand cross-link does not
inhibit the DNA unwinding or the ATPase activities of
RecA, but it inhibits both the helicase and DNA-dependent
ATPase activities of the RecB protein [49]. It would be
interesting to further investigate the effect of cisplatin DNA
cross-links on the in vitro activities of the RecBCD holo-
enzyme and the other recombinases (RuvABC and RecG).
We must note that the interstrand cross-link, although a
minor adduct formed by cisplatin (~2% of all adducts), is
also a viable candidate for the lethal lesion. The precise
mechanism for repair of interstrand cross-links is not, as
yet, understood, but it is believed to involve recombination
and excision repair [1]. It is possible, therefore, that the
interstrand cross-links also contributed to the cisplatin sen-
sitivity of the various recombination mutants. Although we
observed increased sensitivity to cisplatin by the recombi-
nation/NER double mutants, we cannot exclude the possi-
bility that there is partial overlap in activities of the two
pathways in repair of this (or other minor) subset of cis-
platin adducts. A further understanding of how the individ-
ual cisplatin cross-links are processed by specific
recombination and repair strategies could provide insights
into identification of the specific adduct(s) responsible for
the therapeutic activity of the drug.
Although our study is a genetic analysis of recombinational
pathways of tolerance/repair of cisplatin-induced DNA
damage in bacteria, it is useful to bear in mind the ques-
tion that underlies most research on cisplatin — namely,
why are tumors of the testis so singularly susceptible to the
drug? The detailed molecular mechanism that can account
for the striking organotropism of cisplatin is yet to be dis-
covered. From the perspective of our present study,
several observations of possible relevance have been
made. Firstly, the majority of testicular tumors (95%)
derive from germ cells [50], which are unique in that they
require recombination for meiotic crossing-over and proper
chromosome segregation during cell division. In addition
to our findings that cisplatin is highly recombinogenic in
bacteria, it has been shown that cisplatin can induce high
levels of recombination in mouse testicular germ cells [11].
Cisplatin also causes abnormal homologue pairing, and it
disrupts the proper formation and resolution of recombina-
tion intermediates during testicular germ cell meiosis
[51,52]. Secondly, testicular tissues have been found to
overexpress several mismatch repair (MMR) proteins
including MSH2, MSH4, MLH1 and MSH5 [47,53–56].
One function of MMR proteins is to ensure the fidelity
and regulate the levels of recombination, and to enable
completion of meiotic cell division. Thirdly, resistance to a
number of DNA-damaging agents, including cisplatin and
alkylators, correlates with the loss of MMR proteins, both
in E. coli and in eukaryotes [8,57]. Thus, MMR proteins
paradoxically seem to sensitize rather than protect cells
from cisplatin and some other DNA damaging agents.
How MMR contributes to cisplatin toxicity is not under-
stood, but it has been proposed that MMR proteins initiate
abortive repair opposite cisplatin adducts [57], or inhibit
recombination-dependent bypass of the adducts during
replication [58]. At least one apoptotic pathway for cis-
platin-induced cell death (that involving p73) requires an
MMR protein, MLH1 [59]. Moreover, some MMR pro-
teins specifically recognize cisplatin-damaged DNA
[46–48]. We propose that the relationships among these
observations provide a framework within which we might
begin to understand the molecular mechanism for the
organotropic action of this drug. For example, high levels
of cisplatin-induced recombination could lead to cell death
by triggering MMR-mediated damage signaling pathways
that are specific to germ cells. The abundant MMR pro-
teins could also sensitize germ cells by interfering with the
required high level of recombinational repair of cisplatin
damage. Further exploration of the relationships among
recombination, repair of DNA damage, and the roles of
MMR proteins in both of these processes are warranted. 
Finally, in our study of DNA-damaging agents that induce
recombination (Figure 7), only MMC rivaled cisplatin as a
recombinogen. It is noteworthy that this drug, like cis-
platin, is differentially toxic to testicular cancer cells
in vitro [60]. It is tempting to speculate that induced
recombination might be the common denominator in the
mechanism of action of a specific class of anticancer agents.
Understanding the role of recombination in genome main-
tenance could, therefore, be of great significance for future
tissue-specific drug design efforts.
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Significance
Many antitumor drugs extend life but do not completely
cure cancer. The DNA-damaging anticancer compound
cisplatin is one exception; therapeutic regimens including
cisplatin as the principal chemotherapeutic agent afford
an essential cure for testicular cancer and delay the pro-
gression of ovarian and several other cancers. In the past
decade, several different and non-mutually exclusive
hypotheses have been put forth to explain the cytotoxic
and organotropic effects of this compound. It is well estab-
lished that the cytotoxicity of cisplatin derives from its
ability to form covalent DNA adducts and, because these
adducts can be removed from DNA by nucleotide exci-
sion repair (NER), NER has long been considered the
central player in countering cisplatin cytotoxicity. The
present study shows that recombination is an equally crit-
ical genoprotective system as NER against cisplatin-
induced DNA damage. Using a battery of single and
double mutants, we have determined firstly, that cisplatin-
damaged DNA leads to the formation of multiple replica-
tion (or repair) intermediates that utilize recombination
strategies for their resolution, secondly, that these recom-
bination pathways appear to be non-overlapping with
NER in the processing of cisplatin DNA damage, and
thirdly, that such recombination strategies are quantita-
tively of equal importance as NER for cell survival fol-
lowing cisplatin DNA damage. Moreover, the work
shows that cisplatin and mitomycin C (another clinically
used drug), in comparison to a panel of other DNA-dam-
aging agents, were able to induce recombination at doses
that were minimally toxic. It is possible that there is an
important connection between the capacity of cisplatin to
induce robust levels of recombination and the therapeutic
specificity of this drug for testicular tumors. Testicular
tumors derive from germ cells, which are cells that are
unique in that they undergo meiotic recombination as an
essential step during cell division. Meiotic recombination
is a highly regulated and a precise event, and if disrupted,
germ cells enter apoptosis. Cancer cells derived from
germ cells might inherit such regulatory mechanisms spe-
cific for meiotic recombination, which might be triggered
by cisplatin-induced recombination events. Thus,
although recombination is a powerful protective pathway
against cisplatin-induced damage, it might actually selec-
tively sensitize germ cells and germ cell tumors to the
drug. 
Materials and methods
Chemicals
Methylmethane sulfonate was obtained from Eastman–Kodak, and mit-
omycin C and streptozotocin were from Sigma. N-Methyl-N′-nitro-N-
nitrosoguanidine, cis- and trans-diamminedichloroplatinum(II) were
from Aldrich.
Bacterial strains
The mutant strains that were used in this study are listed in Table 1. All
the strains used for cytotoxicity studies are derivatives of AB1157. The
auxotrophic phenotype of all mutant strains was confirmed by growth
on the appropriate supplemented minimal medium.
Cytotoxicity assay
Overnight cultures were diluted 1000-fold and grown in Luria-Bertani
(LB) medium [61] until the density of the populations reached
2 × 108 cells/ml as determined by OD600. The exponentially growing cells
were resuspended in M9 minimal medium [61] and treated with drug dis-
solved in H2O for 2 hr at 37°C. Appropriate dilutions in M9 medium were
plated on LB plates and incubated at 37°C until colonies could be
scored. Results from three to six independent experiments plated in
duplicate were averaged and plotted against drug concentration.
Drug-induced recombination assay
Strain GM7330 carries a specially constructed non-tandem duplication
of partially deleted lac operons (lacMS286φ80dIIlacBK1). φ80dIIlacBK1
has a small deletion in the proximal portion of the lacZ gene, whereas
lacMS286 contains a distal deletion. The deletions are non-overlapping,
so functional Lac+ revertants result only after a recombination event. The
construction and properties of lac duplication strains have been
described elsewhere [62].
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Table 1
Genotypes of E. coli K-12 strains.
Strain Genotype Source
AB1157 thr-1 ara-14 leuB6–(gpt-proA)62 lacY1 E.A. Adelberg
tsx-33 glnV44(AS) galK2(Oc) hisG4(Oc)
rfbD1 mgl-51 rpoS396(Am) rpsL31(StrR)
kdgK51 xylA5 mtl-1 argE3(Oc) thi-1
AB2500 As AB1157 but uvrA6 deoB16 thyA12 W.D. Rupp
AM207 As AB1157 but recR252::mTn10 R.G. Lloyd
AM547 As AB1157 but ∆ruvABC65 R.G. Lloyd
C266 As AB1157 but recG258::Kan F. Stahl
CS85 As AB1157 but ruvC53 eda51::Tn10 R.G. Lloyd
GM5560 As AB1157 but recA56 srl300::Tn10 Lab stock
GM5593 As AB1157 but uvrA6 ruvA60::Tn10 Lab stock
GM5598 As AB1157 but uvrA6 ruvC64::Kan Lab stock
GM7330 ∆lacMS286φ80dIIlacBK1 ara thi(?) Lab stock
GM7522 As AB1157 but uvrA6 recBCD::Kan Lab stock
JC5519 As AB1157 but recB21 recC22 A.J. Clark
JC3913 As AB1157 but uvrA6 recF143 M. Volkert
JC9239 As AB1157 but recF143 A.J. Clark
KM21 As AB1157 but ∆recBCD::Kan K.M. Murphy
KM353 As AB1157 but recD1901::Tn10 K.M. Murphy
N2057 As AB1157 but ruvA60::Tn10 R.G. Lloyd
N2445 As AB1157 but recO1504::Tn5 R.G. Lloyd
N3398 As AB1157 but recG258::Kan ruvC53 R.G. Lloyd
eda51::Tn10
All strains are F–. Am, amber mutation; AS, amber suppressor; ∆,
deletion; Oc, ochre mutation; Str, streptomycin; Kan, kanamycin; Tn5
and Tn10 encode kanamycin and tetracycline resistance respectively;
mTn10, miniTn10.
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Strain GM7330 was grown overnight in LB medium and diluted ten-
fold in minimal salts without glucose [63]. Diluted cells (1.5 ml) were
added to MacConkey agar plates (Difco; supplemented with 1%
lactose), the cells were allowed to settle for 10 min, and then the
excess medium was removed by aspiration. This procedure produced a
uniform lawn of cells on the plate. Sterile 6.35 mm disks (Difco) were
placed on each dry plate and aliquots of drug were added to the disks.
Not more than 10 µl were spotted on the disks at one time and the
disks were allowed to dry before further addition of drug. In this
manner, the drug was delivered by diffusion from the disk, yielding a
gradient of drug concentration that decreased with distance from the
disk. The low solubility of trans-diamminedichloroplatinum(II) (trans-
DDP) precluded testing at higher doses than those presented. The
plates were then incubated for 48 hr at 37°C. Plates were scanned
(bottom down) with a Umax 1220 scanner and CorelDraw software.
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